Startup logs ₹62 crore in revenue and ₹12 crore profit before tax in FY25

Mumbai, July 28, 2025 Cancer therapy startup ImmunoAct has achieved a major milestone. It logged ₹62 crore in revenue and ₹12 crore in profit before tax in FY25. The achievement marks a rare feat in India’s biotech startup space, where most early-stage firms struggle with profitability. The company’s success came from its cost-effective CAR-T therapy. It is now gaining traction among hospitals and patients seeking affordable treatment.

ImmunoAct, backed by Hyderabad-based Laurus Labs with a 94% stake, has shown impressive financial performance in its first full operational year. The company’s flagship product, NexCAR19, is India’s first indigenously developed CAR-T (Chimeric Antigen Receptor T-cell) therapy. According to sources, the firm’s financial turnaround stems from strong market adoption of its one-time infusion therapy, which provides longer remission compared to traditional methods like immunotherapy and bone marrow transplants.

Founded in 2013 by immunologist Rahul Purwar, a professor at IIT Bombay’s bioengineering department, ImmunoAct was spun off from academic research into a full-fledged commercial venture. In FY25 alone, NexCAR19 generated all of the ₹62 crore revenue, solidifying its commercial appeal in India’s oncology space. The company expects continued growth as affordability improves access to its treatment.

Each dose of NexCAR19, initially priced at ₹42 lakh, now costs around ₹30 lakh. The company anticipates further price reductions as demand increases and economies of scale take effect. The lower pricing strategy has been crucial in drawing patients from both public and private hospital systems.

In addition to financial growth, ImmunoAct recently appointed V Simpson Emmanuel, former managing director of Roche India, as strategic advisor. His appointment signals the firm’s intent to scale commercially and expand into broader markets, both domestic and international.

Founder Rahul Purwar emphasized the importance of commercial leadership in biotech innovation. “We needed someone who understands not just the commercial landscape, but also the nuances of innovation, patient outcomes, and long-term viability,” he said. With NexCAR19’s success, the company is now positioning itself as a leading cancer therapy provider built on indigenous research.

Source